Traversa Inks Deal to Evaluate siRNA Delivery Technology with Sanofi-Aventis

Under the agreement, the companies will examine the ability of the PTD-DRBD technology to deliver siRNAs against undisclosed targets, with an eye toward developing RNAi therapeutics.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.